Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare "Dual Eligible" Transition To Be Topic Of CMS Meeting With States

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS will meet with the National Governors Association and the Council of State Governments to develop state-specific plans for making the transition from Medicaid to Medicare Rx. CMS Administrator McClellan highlights the meeting as one of the agency's actions to ensure dual eligibles maintain access to prescriptions.

You may also be interested in...

One-Time Scripts For Non-Formulary Drugs Could Aid Part D Transition – CMS

Medicare Part D plans should provide a temporary “first-fill” prescription for new beneficiaries taking non-formulary drugs, CMS says. A 30-day supply “may be reasonable” for most beneficiaries, but for patients in long-term care “a transition period of 90 to 180 days might be appropriate.”

CMS Urging States To Provide Extended-Supply Scripts To "Dual-Eligibles"

Prescriptions for 60- or 90-day supplies given to dual-eligibles at the end of 2005 would still receive federal matching coverage for state Medicaid programs and could decrease the likelihood of beneficiary coverage gaps, CMS Deputy Administrator Norwalk says.

SEC Seeks Vaccine Manufacturer Input On Pediatric Stockpile Accounting

Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts